Viking Therapeutics stock soared 21% in early trade Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The study of VK2735 amo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback